Companies 2seventy bio
2seventy bio CEO salary & total pay, FY2023: $9.1M
2seventy bio (TSVT) CEO salary, fiscal 2023: Nick Leschly was paid a salary of $798,532 and $9,084,554 in total compensation. Free brief. Every figure links to the company’s own filing.
2seventy bio no longer files a proxy statement; its last pay data is FY2023.
Nick Leschly's complete compensation dossier
A PDF and a CSV sent to your email: Nick Leschly's pay in every fiscal year 2seventy bio reported it, line by line, with Nick Leschly's equity grants and 2seventy bio's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $6,078,514FY2022
- $9,084,554FY2023
CEO total pay was $9,084,554 in fiscal 2023, up from $6,078,514 in fiscal 2022.
FY2023: salary $798,532 · bonus $0 · stock awards $6,729,637 · option awards $1,543,185
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Nick Leschly | $798,532 | $0 | $6,729,637 | $1,543,185 | $0 | $0 | $13,200 | $9,084,554 |
| President, Chief Executive Officer | ||||||||
| Philip Gregory | 533,219 | 120,083 | 2,215,712 | 474,826 | 0 | 0 | 13,200 | 3,357,040 |
| Chief Scientific Officer | ||||||||
| William Baird III | 518,119 | 116,685 | 1,744,288 | 474,826 | 0 | 0 | 73,200 | 2,927,118 |
| Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2023 total | FY2022 total | FY2021 total | Δ FY2022→2023 |
|---|---|---|---|---|
| Nick Leschly | $9,084,554 | $6,078,514 | — | ↑ +3,006,040 |
| Philip Gregory | 3,357,040 | 2,531,347 | — | ↑ +825,693 |
| William Baird III | 2,927,118 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our Compensation Committee reviews and approves the compensation of our executive officers and is primarily responsible for determining the compensation for the named executive officers consistent with our overall executive compensation philosophy. The Committee considers our overall performance against goals, individual executive performance, and internal and external equity as key factors in those decisions.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Aon |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2023
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Philip Gregory | Option | 6,419 | 144 | 114.67 | — |
| Philip Gregory | Option | 11,706 | 4,393 | 44.17 | — |
| Philip Gregory | Option | 44,650 | 50,350 | 13.41 | — |
| Philip Gregory | Option | — | 50,000 | 13.2 | — |
| Philip Gregory | RSU | — | 821 | — | 3,506 |
| Philip Gregory | RSU | — | 4,025 | — | 17,187 |
| Philip Gregory | RSU | — | 35,625 | — | 152,119 |
| Philip Gregory | RSU | — | 25,000 | — | 106,750 |
| Philip Gregory | RSU | — | 142,857 | — | 609,999 |
| Philip Gregory | Option | 2,034 | — | 78.44 | — |
| Philip Gregory | Option | 8,204 | — | 117.4 | — |
| Nick Leschly | Option | 20,872 | 459 | 114.67 | — |
| Nick Leschly | Option | 42,248 | 15,709 | 44.17 | — |
| Nick Leschly | Option | 125,490 | 141,510 | 13.41 | — |
| Nick Leschly | Option | — | 162,500 | 13.2 | — |
| Nick Leschly | RSU | — | 2,667 | — | 11,388 |
| Nick Leschly | RSU | — | 5,797 | — | 24,753 |
| Nick Leschly | RSU | — | 100,125 | — | 427,534 |
| Nick Leschly | RSU | — | 81,250 | — | 346,938 |
| Nick Leschly | RSU | — | 428,571 | — | 1,829,998 |
| Nick Leschly | Option | 54,149 | — | 38 | — |
| Nick Leschly | Option | 29,535 | — | 78.44 | — |
| Nick Leschly | Option | 36,099 | — | 117.4 | — |
| William Baird III | Option | 6,419 | 144 | 114.67 | — |
| William Baird III | Option | 11,706 | 4,392 | 44.17 | — |
| William Baird III | Option | 31,725 | 35,775 | 13.41 | — |
| William Baird III | Option | — | 50,000 | 13.2 | — |
| William Baird III | RSU | — | 821 | — | 3,506 |
| William Baird III | RSU | — | 4,025 | — | 17,187 |
| William Baird III | RSU | — | 25,312 | — | 108,082 |
| William Baird III | RSU | — | 25,000 | — | 106,750 |
| William Baird III | RSU | — | 107,143 | — | 457,501 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Wei Lin, M.D., Ph.DIndependent · Nominating and Corporate Governance | $61,250 | $230,708 | $330,090 | — | — | $622,048 |
| Daniel S. LynchIndependent · Audit · Compensation (Chair) · Not standing for re-election | 104,000 | 99,204 | 133,298 | — | — | 336,502 |
| Denice TorresIndependent · Lead Independent Director · Audit · Compensation · Nominating and Corporate Governance (Chair) | 71,500 | 99,204 | 133,298 | — | — | 304,002 |
| Sarah GlickmanIndependent · Audit (Chair) · Compensation | 70,500 | 99,204 | 133,298 | — | — | 303,002 |
| Marcela Maus, M.D., Ph.DIndependent · Nominating and Corporate Governance | 57,500 | 99,204 | 133,298 | — | — | 290,002 |
| Ramy Ibrahim, M.DIndependent · Departed during FY | 32,500 | 99,204 | 132,360 | — | — | 264,064 |
Board fee structure and ownership guideline
| Annual cash retainer | $45,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 18,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2023 |
|---|---|
| Cash retainers and fees | $397,250 |
| Equity awards (grant-date value) | $726,728 |
| All other compensation | $0 |
| Total cost of the board | $1,123,978 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names 2seventy bio as a peer
Companies that benchmark against TSVT
2 companies name TSVT as a compensation peer
- ADC Therapeutics SAADCTFY2025
- AGENUS INCAGENFY2025
- Generation Bio Co.GBIOFY2024
- MACROGENICS INCMGNXFY2025
- REGENXBIO Inc.RGNXFY2024
- RIGEL PHARMACEUTICALS INCRIGLFY2025
Each company listed discloses TSVT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named TSVT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | 2seventy bio | 2023 | Nick Leschly | $798,532 | $6,729,637 | $1,543,185 | $0 | $9,084,554 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | — | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2024 | — | —a |
a. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jessica Snow | See Remarks | 2024-05-03 | D | 15 | $5 | $74 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-06-03 | D | 649 | 4 | 2,714 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2024-06-03 | D | 1,167 | 4 | 4,881 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2024-06-10 | A | 12,050 | 4 | 47,357 | Derivative, Class A Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2024-06-10 | A | 6,025 | — | — | Common | Form 4 ↗ |
| Charles W. Newton | Director | 2024-06-10 | A | 12,050 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2024-06-10 | A | 6,025 | 0 | 0 | Common | Form 4 ↗ |
| Denice Torres | Director | 2024-06-10 | A | 24,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2024-06-10 | A | 12,050 | 0 | 0 | Common | Form 4 ↗ |
| Sarah Glickman | Director | 2024-06-10 | A | 24,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sarah Glickman | Director | 2024-06-10 | A | 12,050 | 0 | 0 | Common | Form 4 ↗ |
| Lin Wei | Director | 2024-06-10 | A | 24,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lin Wei | Director | 2024-06-10 | A | 12,050 | 0 | 0 | Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2024-06-10 | A | 24,100 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2024-06-10 | A | 12,050 | 0 | 0 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2024-07-01 | A | 245,864 | 0 | 0 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-07-01 | A | 108,538 | 0 | 0 | Common | Form 4 ↗ |
| William Baird III | Director | 2024-07-01 | A | 586,022 | 0 | 0 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2024-07-02 | D | 12 | 4 | 48 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-07-02 | D | 14 | 4 | 56 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2024-08-05 | D | 13 | 4 | 52 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-08-14 | D | 7,816 | 4 | 33,760 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2024-10-03 | D | 1,230 | 5 | 5,718 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-10-03 | D | 679 | 5 | 3,157 | Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2024-11-18 | D | 3,900 | 3 | 13,182 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2024-12-13 | D | 2,287 | 3 | 7,393 | Common | Form 4 ↗ |
| William Baird III | Director | 2025-01-03 | D | 31,718 | 3 | 93,121 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-01-03 | D | 1,013 | 3 | 2,974 | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-01-03 | D | 85,978 | 3 | 252,423 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-03 | D | 1,000 | 3 | 2,936 | Common | Form 4 ↗ |
| William Baird III | Director | 2025-01-06 | A | 176,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William Baird III | Director | 2025-01-06 | A | 264,000 | 0 | 0 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-01-06 | A | 72,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-01-06 | A | 108,000 | 0 | 0 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-06 | A | 70,750 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-06 | A | 106,150 | 0 | 0 | Common | Form 4 ↗ |
| William Baird III | Director | 2025-01-06 | D | 763 | 3 | 2,120 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-01-06 | D | 97 | 3 | 270 | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-01-06 | D | 892 | 3 | 2,478 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-06 | D | 5,000 | 3 | 13,972 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-06 | D | 114 | 3 | 317 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-06 | D | 1,838 | 3 | 5,136 | Common | Form 4 ↗ |
| Jessica Snow | See Remarks | 2025-01-07 | D | 186 | 3 | 491 | Common | Form 4 ↗ |
| Kynam Global Healthcare Master Fund, LP | Greater-than-10% holder | 2025-03-11 | D | 5,142,111 | 5 | 25,350,607 | Common | Form 4 ↗ |
| Kynam Global Healthcare Master Fund, LP | Greater-than-10% holder | 2025-03-11 | D | 5,142,111 | 5 | 25,350,607 | Common | Form 4 ↗ |
| Kynam Global Healthcare Master Fund, LP | Greater-than-10% holder | 2025-03-11 | D | 5,953,825 | 5 | 29,352,357 | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-03-17 | D | 2,592 | 5 | 12,817 | Common | Form 4 ↗ |
| William Baird III | Director | 2025-03-17 | D | 5,092 | 5 | 25,180 | Common | Form 4 ↗ |
| Jessica Snow | Chief Operating Officer | 2025-03-17 | D | 2,298 | 5 | 11,364 | Common | Form 4 ↗ |
| William Baird III | Director | 2025-05-13 | D | 176,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Baird III | Director | 2025-05-13 | D | 182,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| William Baird III | Director | 2025-05-13 | D | 118,209 | — | — | Common | Form 4 ↗ |
| William Baird III | Director | 2025-05-13 | D | 1,002,825 | — | — | Common | Form 4 ↗ |
| Denice Torres | Director | 2025-05-13 | D | 24,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Denice Torres | Director | 2025-05-13 | D | 19,510 | — | — | Common | Form 4 ↗ |
| Denice Torres | Director | 2025-05-13 | D | 12,050 | — | — | Common | Form 4 ↗ |
| Charles W. Newton | Director | 2025-05-13 | D | 12,050 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2025-05-13 | D | 33,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Charles W. Newton | Director | 2025-05-13 | D | 5,533 | — | — | Common | Form 4 ↗ |
| Charles W. Newton | Director | 2025-05-13 | D | 17,092 | — | — | Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2025-05-13 | D | 24,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2025-05-13 | D | 11,702 | — | — | Common | Form 4 ↗ |
| Marcela Maus V. | Director | 2025-05-13 | D | 12,050 | — | — | Common | Form 4 ↗ |
| Lin Wei | Director | 2025-05-13 | D | 24,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Lin Wei | Director | 2025-05-13 | D | 15,267 | — | — | Common | Form 4 ↗ |
| Lin Wei | Director | 2025-05-13 | D | 17,583 | — | — | Common | Form 4 ↗ |
| Jessica Snow | Chief Operating Officer | 2025-05-13 | D | 70,750 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jessica Snow | Chief Operating Officer | 2025-05-13 | D | 18,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Jessica Snow | Chief Operating Officer | 2025-05-13 | D | 11,064 | — | — | Common | Form 4 ↗ |
| Jessica Snow | Chief Operating Officer | 2025-05-13 | D | 247,230 | — | — | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-05-13 | D | 72,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-05-13 | D | 18,300 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-05-13 | D | 21,700 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-05-13 | D | 43,276 | — | — | Common | Form 4 ↗ |
| Victoria Eatwell | Chief Financial Officer | 2025-05-13 | D | 401,111 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-13 | D | 469,000 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-13 | D | 41,000 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-13 | D | 15,233 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-13 | D | 897,642 | — | — | Common | Form 4 ↗ |
| Nick Leschly | Director | 2025-05-13 | D | 335,964 | — | — | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2025-05-13 | D | 33,400 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2025-05-13 | D | 12,050 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2025-05-13 | D | 2,000,000 | 5 | 10,000,000 | Common | Form 4 ↗ |
| Casdin Capital, LLC | Director | 2025-05-13 | D | 22,625 | 5 | 113,125 | Common | Form 4 ↗ |
| Sarah Glickman | Director | 2025-05-13 | D | 24,100 | — | — | Derivative, Class A Common | Form 4 ↗ |
| Sarah Glickman | Director | 2025-05-13 | D | 15,602 | — | — | Common | Form 4 ↗ |
| Sarah Glickman | Director | 2025-05-13 | D | 12,050 | — | — | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (100 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Nick Leschly. DEF 14A, filed 2024-04-25. Section “Executive Compensation” · page 16. As printed: 9,084,554. View filing ↗
- Section 01, Philip Gregory. DEF 14A, filed 2024-04-25. Section “Executive Compensation” · page 16. As printed: 3,357,040. View filing ↗
- Section 01, William Baird III. DEF 14A, filed 2024-04-25. Section “Executive Compensation” · page 16. As printed: 2,927,118. View filing ↗
- Section 08, Wei Lin, M.D., Ph.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 622,048. View filing ↗
- Section 08, Daniel S. Lynch. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 336,502. View filing ↗
- Section 08, Denice Torres. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 304,002. View filing ↗
- Section 08, Sarah Glickman. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 303,002. View filing ↗
- Section 08, Marcela Maus, M.D., Ph.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 290,002. View filing ↗
- Section 08, Ramy Ibrahim, M.D. DEF 14A, filed 2024-04-25. Section “Director Compensation”. As printed: 264,064. View filing ↗
- Section 02, Jessica Snow 2024-05-03. Form 4, filed 2024-05-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-06-03. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2024-06-03. Form 4, filed 2024-06-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Glickman 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Glickman 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lin Wei 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lin Wei 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2024-06-10. Form 4, filed 2024-06-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2024-07-01. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2024-07-02. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-07-02. Form 4, filed 2024-07-03. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2024-08-05. Form 4, filed 2024-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-08-14. Form 4, filed 2024-08-16. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2024-10-03. Form 4, filed 2024-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-10-03. Form 4, filed 2024-10-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2024-12-13. Form 4, filed 2024-12-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-01-03. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-01-03. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-01-03. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-03. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-06. Form 4, filed 2025-01-08. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-01-06. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-01-06. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-01-06. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-06. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-06. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-06. Form 4, filed 2025-01-22. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-01-07. Form 4, filed 2025-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kynam Global Healthcare Master Fund, LP 2025-03-11. Form 4, filed 2025-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kynam Global Healthcare Master Fund, LP 2025-03-11. Form 4, filed 2025-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kynam Global Healthcare Master Fund, LP 2025-03-11. Form 4, filed 2025-03-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-03-17. Form 4, filed 2025-03-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-03-17. Form 4, filed 2025-03-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-03-17. Form 4, filed 2025-03-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, William Baird III 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Denice Torres 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Charles W. Newton 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marcela Maus V. 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lin Wei 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lin Wei 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Lin Wei 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jessica Snow 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Victoria Eatwell 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nick Leschly 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Casdin Capital, LLC 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Glickman 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Glickman 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Sarah Glickman 2025-05-13. Form 4, filed 2025-05-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-03-07. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 397,250 + equity 726,728 + all other 0 = 1,123,978, summed across the director compensation table rows.
- 2seventy bio (subject), Section 10b CEO total. DEF 14A, filed 2024-04-25. CEO total compensation as printed in 2seventy bio's own proxy. As printed: 9,084,554. View filing ↗